Vinpocetine not only in cerebral circulatory disorders Reprint from: Biblioteka Medycyny Faktów 1/2013
Article Sidebar
Published:
Mar 31, 2014
Keywords:
vinpocetine, cerebrovascular disease, neuroprotection, multidirectional action
Main Article Content
Abstract
This paper presents the mechanism of action of vinpocetine omni. Particular attention is given to the application of vinpocetine in many neurological diseases: cerebrovascular disorders, cognitive disorders, vascular dementia, stroke brain. Attention was drawn to apply in otolaryngology and ophthalmology. Also a significant safety profile and low side effects were indicated.
Article Details
How to Cite
Porębska, B. (2014). Vinpocetine not only in cerebral circulatory disorders. Medycyna Faktow (J EBM), 7(1(22), 23-26. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2377
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Zaremba M., Postuła M.: Wielokierunkowe działanie winpocetyny i korzyści z tym związane w świetle badań eksperymentalnych i klinicznych. Medycyna Faktów 2013; 6(2).
2. Bałkowiec-Iskra E., Joniec I.: Winpocetyna nowe wskazania do stosowania. Przew. Lek. 2005; 2: 32-39.
3. Miyata N., Yamaura H., Tanaka M. et al.: Effects of VA-045, a novel apovincaminic acid derivative, on isolated blood vessels: cerebroarterial selectivity. Life Sci. 1993; 52: 181-186.
4. Sitges M., Galván E., Nekrassov V.: Vinpocetine blockade of sodium channels inhibits the rise in sodium and calcium induced by 4-aminopyridine in synaptosome. Neurochem. Int. 2005; 46: 533-540.
5. Stolc S.: Indole derivatives as neuroprotectants. Life Sci. 1999; 65: 1943-1950.
6. Matsukawa M., Ogawa M., Nakadate K. et al.: Serotonin and acetylcholine are crucial to maintain hippocampal synapses and memory acquisition in rats. Neurosci. Lett. 1997; 230: 13-16.
7. Shibuya T., Sato K.: Effects of vinpocetine on experimental brain ischemia, histological study of brain monomines. Igaku No Ayumi 1986; 139: 217-219.
8. McDaniel M.A., Maier S.F., Einstein G.O.: Brain-specific nutrients: a memory cure? Nutrition 2003; 19: 957-975.
9. Feher G., Koltai K., Kesmarky G. et al.: Effect of parenteral or oral vinpocetine on the hemorheological parameters of patients with chronic cerebrovascular diseases. Phytomedicine 2009; 16: 111-117.
10. Szapáry L., Horváth B., Alexy T. et al.: [Effect of vinpocetine on the hemorheologic parameters in patients with chronic cerebrovascular disease]. Orv. Hetil. 2003; 144: 973-978.
11. Tohgi H., Sasaki K., Chiba K., Nozaki Y.: Effect of vinpocetine on oxygen release of hemoglobin and erythrocyte organic polyphosphate concentrations in patients with vascular dementia of the Binswanger type. Arzneimittelforschung 1990; 40: 640-643.
12. Valikovics A.: [Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions]. Ideggyogy Sz. 2007; 60: 301-310.
13. Balestreri R., Fontana L., Astengo F.: A double-blind placebo controlled evasenile evaluation of the safety and efficacy of vinpocetine in the treatment of patient with chronic vascular senile cerebral dysfunction. J. Am. Geriatr. Soc. 1987; 35: 425-30.
14. Yamaguchi T., Nagano H., Yamaguchi M.: The effects of kallidinogenase on choroidal blood flow in a hypertensive rabbit model. Curr. Eye Res. 1999; 18(6): 417-22.
15. Nekrassov V., Sitges M.: Vinpocetine protects from aminoglycoside antibiotic-induced hearing loss in guinea pig in vivo. Brain Res. 2000; 868: 222-9.
16. Truss M.C., Stief C., Uckert S. et al.: Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to beside. World J. Urol. 2001; 19: 344-50.
17. Nosalova V., Machova J., Babulova A.: Protective action of vinpocetine against experimentally induced gastric damage in rats. Arzneimittelforschung 1993; 43: 981-985.
18. Hadjiev D.: Asymptomatic ischemic cerebrovascular disorders and neuroprotection with vinpocetine. Ideggyogy Sz. 2003; 56(5–6): 166-72.
19. Gaal L., Monar P.: Effect of vinopocetine on noradrenergic neurons in rat locus coeruleus. Eur. J. Phamacol. 1990; 187: 537-539.
2. Bałkowiec-Iskra E., Joniec I.: Winpocetyna nowe wskazania do stosowania. Przew. Lek. 2005; 2: 32-39.
3. Miyata N., Yamaura H., Tanaka M. et al.: Effects of VA-045, a novel apovincaminic acid derivative, on isolated blood vessels: cerebroarterial selectivity. Life Sci. 1993; 52: 181-186.
4. Sitges M., Galván E., Nekrassov V.: Vinpocetine blockade of sodium channels inhibits the rise in sodium and calcium induced by 4-aminopyridine in synaptosome. Neurochem. Int. 2005; 46: 533-540.
5. Stolc S.: Indole derivatives as neuroprotectants. Life Sci. 1999; 65: 1943-1950.
6. Matsukawa M., Ogawa M., Nakadate K. et al.: Serotonin and acetylcholine are crucial to maintain hippocampal synapses and memory acquisition in rats. Neurosci. Lett. 1997; 230: 13-16.
7. Shibuya T., Sato K.: Effects of vinpocetine on experimental brain ischemia, histological study of brain monomines. Igaku No Ayumi 1986; 139: 217-219.
8. McDaniel M.A., Maier S.F., Einstein G.O.: Brain-specific nutrients: a memory cure? Nutrition 2003; 19: 957-975.
9. Feher G., Koltai K., Kesmarky G. et al.: Effect of parenteral or oral vinpocetine on the hemorheological parameters of patients with chronic cerebrovascular diseases. Phytomedicine 2009; 16: 111-117.
10. Szapáry L., Horváth B., Alexy T. et al.: [Effect of vinpocetine on the hemorheologic parameters in patients with chronic cerebrovascular disease]. Orv. Hetil. 2003; 144: 973-978.
11. Tohgi H., Sasaki K., Chiba K., Nozaki Y.: Effect of vinpocetine on oxygen release of hemoglobin and erythrocyte organic polyphosphate concentrations in patients with vascular dementia of the Binswanger type. Arzneimittelforschung 1990; 40: 640-643.
12. Valikovics A.: [Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions]. Ideggyogy Sz. 2007; 60: 301-310.
13. Balestreri R., Fontana L., Astengo F.: A double-blind placebo controlled evasenile evaluation of the safety and efficacy of vinpocetine in the treatment of patient with chronic vascular senile cerebral dysfunction. J. Am. Geriatr. Soc. 1987; 35: 425-30.
14. Yamaguchi T., Nagano H., Yamaguchi M.: The effects of kallidinogenase on choroidal blood flow in a hypertensive rabbit model. Curr. Eye Res. 1999; 18(6): 417-22.
15. Nekrassov V., Sitges M.: Vinpocetine protects from aminoglycoside antibiotic-induced hearing loss in guinea pig in vivo. Brain Res. 2000; 868: 222-9.
16. Truss M.C., Stief C., Uckert S. et al.: Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: from bench to beside. World J. Urol. 2001; 19: 344-50.
17. Nosalova V., Machova J., Babulova A.: Protective action of vinpocetine against experimentally induced gastric damage in rats. Arzneimittelforschung 1993; 43: 981-985.
18. Hadjiev D.: Asymptomatic ischemic cerebrovascular disorders and neuroprotection with vinpocetine. Ideggyogy Sz. 2003; 56(5–6): 166-72.
19. Gaal L., Monar P.: Effect of vinopocetine on noradrenergic neurons in rat locus coeruleus. Eur. J. Phamacol. 1990; 187: 537-539.